Publications

Publications

Presentations

Efavirenz versus nevirapine-based initial treatment of HIV infection: clinical and virological outcomes in Southern African adults

Nachega JB, Hislop M, Dowdy DW, Gallant JE, Chaisson RE, Regensberg L, Maartens G. Efavirenz versus nevirapine-based initial treatment of HIV infection: clinical and virological outcomes in Southern African adults. AIDS. 2008 Oct 18; 22(16):2117-25.

Pharmacy refill adherence compared with CD4 count changes for monitoring HIV-infected adults on antiretroviral therapy

Bisson GP, Gross R, Bellamy S, Chittams J, Hislop M, Regensberg L, Frank I, Maartens G, Nachega JB. Pharmacy refill adherence compared with CD4 count changes for monitoring HIV-infected adults on antiretroviral therapy. PLoS Medicine. 2008 May 20; 5(5):e109.

Adherence to Non-Nucleoside Reverse Transcriptase-based HIV Therapies and Virologic Outcomes

Nachega JB, Hislop M, Dowdy DW, Chaisson RE, Regensberg L, Maartens G. Adherence to Non-Nucleoside Reverse Transcriptase-based HIV Therapies and Virologic Outcomes. Annals of Internal Medicine. 2007:146(8):564-73.

HIV and AIDS, STI and TB in the Private Sector

Stevens M, Sinanovic E, Regensberg L, Hislop M. HIV and AIDS, STI and TB in the Private Sector. 14, 201-211. In: Harrison S, Bhana R, Ntuli A, editors. South African Health Review 2007. Durban: Health Systems Trust; 2007. URL: http://www.hst.org.za/publications/711.

Adherence to Highly Active Antiretroviral Therapy As Assessed by Pharmacy Claims Predicts Survival in HIV-infected South African Adults

Nachega JB, Hislop M, Dowdy DW, Lo M, Omer SB, Regensberg L, Chaisson RE, Maartens G. Adherence to Highly Active Antiretroviral Therapy As Assessed by Pharmacy Claims Predicts Survival in HIV-infected South African Adults. Journal of Acquired Immune Deficiency Syndromes, 2006, Volume 43, Number 1, 78-84.

Enrolment experience and the measurement of survival in a private sector HIV/AIDS disease management programme

Hislop M, Regensberg L. Enrolment experience and the measurement of survival in a private sector HIV/AIDS disease management programme. South African Journal of HIV Medicine. May 2004, 15 – 17.

Maximising the benefits of antiretroviral therapy: what have we learnt in the private sector?

Regensberg L, Hislop M. Maximising the benefits of antiretroviral therapy: what have we learnt in the private sector? AIDS Analysis Africa. February 2004.

Counting the Cost of Care: do HIV/AIDS Disease Management Programmes Deliver?

Cowlin R, Regensberg L, Hislop M: Counting the Cost of Care: do HIV/AIDS Disease Management Programmes Deliver? AIDS Management Report, 2003, 1(3), 20 – 23.

Aid for AIDS: A report back on more than four years of HIV/AIDS disease management in Southern Africa

Regensberg L, Hislop M. Aid for AIDS: A report back on more than four years of HIV/AIDS disease management in Southern Africa. South African Journal of HIV Medicine. Feb 2003, 7 – 10.

Prevention of vertical transmission of human immunodeficiency type 1 virus in a managed care setting

Regensberg L, Pead C, Mahumapelo J, Cotton M. Prevention of vertical transmission of human immunodeficiency type 1 virus in a managed care setting. South African Medical Journal 2000, 90(11), 1092-1093.